#biotech deals

All articles tagged with "biotech deals"

Novartis Wants More From Avidity Than Muscular Dystrophy Alone

Novartis says it is looking to apply Avidity Biosciences’ underlying science beyond muscular dystrophies as it works to realize more value from its $12 billion acquisition.

Key Takeaways

Novartis says Avidity’s science may have uses beyond muscular dystrophies.
The company tied that view to extracting more value from its $12 billion acquisition.

DT Editorial Team·May 24, 2026·via endpoints.news

Roche and C4 Therapeutics Deepen Their Bet on DACs

Roche is expanding work with longtime partner C4 Therapeutics in a deal worth $20 million upfront, underscoring rising interest in degrader-antibody conjugates as a new twist on an already hot cancer-drug category.

Key Takeaways

Roche is expanding work with C4 Therapeutics in a DAC-focused deal worth $20 million upfront.
Endpoints says DACs are gaining traction as a degrader-based variation on antibody-drug conjugates.

DT Editorial Team·Apr 10, 2026·via endpoints.news

Otsuka’s $700 Million Upfront Deal for Transcend Signals Continued Bet on Next-Generation Neuropsychiatric Drugs

Otsuka is acquiring private biotech Transcend Therapeutics in a deal worth roughly $1.2 billion, extending big pharma’s interest in neuropsychiatric medicines modeled on the therapeutic promise associated with psychedel

Key Takeaways

Otsuka will pay $700 million upfront to acquire Transcend Therapeutics.
The transaction is worth roughly $1.2 billion in total.

DT Editorial Team·Mar 29, 2026·via endpoints.news